Navigation Links
US Professors Develop Fusion Protein to Fight Cancer

Two Oklahoma university professors have claimed significant success in the continuing fight to develop a drug that could target only cancerous cells.

Thomas Pento and Roger HarrisonTwo professors say they have developed a cancer-fighting protein that can stop the spread of certain cancerous cells without damaging healthy, normal cells. The new fusion protein can be helpful in fighting lung, prostate and pancreatic cancers without the damages that are caused by chemo and radiotherapy.

A fusion protein is the product of joining two genes or two proteins or peptides together. Fusion proteins can happen naturally or it can be created artificially in a laboratory for research purposes.

The newly developed protein by Thomas Pento and Roger Harrison can keep some types of cancer cells from ingesting a vital protein called methionine that doesn't affect normal body cells, which can remain healthy under the new treatment.

The new discovery also means that the treatment won't result in hair loss and sickness, the two main side effects of chemo and radiation therapies, which kill normal cells along with cancer cells.

Pinto explains, 'So you can see it would cause a lot less toxicity and it should really be a lot more effective.' The research began with breast cancer and expanded to include other types of solid tumors.

Although the fusion protein is helpful in treating many types of cancers, researchers say it works best against lung, prostate and pancreatic cancers.

Pento said the research started with breast cancer, and early experiments with the fusion protein proved successful. Realizing other types of cancer cells use the same special receptors for taking in methionine, the professors expanded their research to other types of solid tumors.

They found the fusion protein to be just as helpful in fighting lung, prostate and pancreatic cancers. The latter is especially encouraging , Pento said, because there is no cure for pancreatic cancer.

'It could be applicable to many types of cancer,' Pento said, 'but we've found that it's effective for those four types of cancer for sure.'

Despite successful testing to this point, don't expect the treatment to be available in the immediate future. Harrison said the fusion protein will need another round of animal tests before moving on to years of human clinical testing.

Three phases of clinical tests could take two years each.

'So it could be in the order of 10 years,' he said.

'It sounds so far away, but realistically, given the FDA and all the phases of testing, it could be done rapidly.'


'"/>




Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Risk Of Developing Arthritis
4. Developing HIV fighter
5. Missing Protein In Cancer Development
6. Tomatoes Might Inhibit the Development Of Prostate Cancer
7. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
8. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
9. Men Who at Risk Of Developing Prostate Cancer
10. Identifying The Risks Of Developing Schizophrenia
11. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
Breaking Medicine Technology: